Oct. 27 at 11:15 PM
$PACS IF they are able to file and cure all filing deficiencies, this likely immediately trades up to
$20+ if not
$30+. Hard to tell given we don’t have actual revenue and EBITDA for the last 12 months at this point, but even at a discount to
$ENSG multiple this should still imply a share price well north of
$25.
